Collegium Pharmaceutical, INC 8-K filings

Collegium Pharmaceutical's CEO, Joseph Ciaffoni, will step down on May 24, 2024, and Michael Heffernan will serve as Interim CEO while a search for a permanent replacement is conducted.

Collegium Pharmaceutical reported a profitable first quarter of 2024 with record Belbuca revenue and a newly authorized share repurchase program.

Collegium Pharmaceutical has granted Hikma Pharmaceuticals exclusive rights to market authorized generic versions of its Nucynta IR and ER products in the United States.

Collegium Pharmaceutical has announced the redemption of all its outstanding 2.625% Convertible Senior Notes due in 2026, totaling $26.35 million, with a redemption date set for June 14, 2024.

Collegium Pharmaceutical announced record financial results for the fourth quarter and full year 2023, driven by strong revenue growth and disciplined expense management.